A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System

BACKGROUND: Olaparib, the world’s first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA. The current study was to assess olaparib-related adverse events (AEs) of real-world through dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yamin, He, Xucheng, Liu, Yanxin, Wu, Pan, Zhang, Qilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250344/
https://www.ncbi.nlm.nih.gov/pubmed/35789689
http://dx.doi.org/10.2147/CLEP.S365513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250344/
https://www.ncbi.nlm.nih.gov/pubmed/35789689
http://dx.doi.org/10.2147/CLEP.S365513

Ejemplares similares